Brokerages Set PhaseBio Pharmaceuticals Inc (NASDAQ:PHAS) PT at $13.00

Share on StockTwits

PhaseBio Pharmaceuticals Inc (NASDAQ:PHAS) has been assigned an average recommendation of “Buy” from the eight analysts that are covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a hold rating and six have issued a buy rating on the company. The average twelve-month price target among brokers that have covered the stock in the last year is $13.00.

Several research analysts have recently weighed in on the company. Zacks Investment Research downgraded PhaseBio Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, May 12th. Citigroup upped their target price on PhaseBio Pharmaceuticals from $11.00 to $12.00 in a research note on Friday, May 29th. Stifel Nicolaus reaffirmed a “buy” rating and set a $4.00 target price on shares of PhaseBio Pharmaceuticals in a research note on Tuesday, May 5th. ValuEngine raised PhaseBio Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Tuesday, March 17th. Finally, Needham & Company LLC assumed coverage on PhaseBio Pharmaceuticals in a research note on Thursday, May 28th. They set a “buy” rating and a $18.00 target price for the company.

Hedge funds and other institutional investors have recently bought and sold shares of the stock. State Street Corp raised its stake in PhaseBio Pharmaceuticals by 3.9% in the 4th quarter. State Street Corp now owns 229,779 shares of the company’s stock valued at $1,404,000 after purchasing an additional 8,537 shares during the last quarter. Barclays PLC raised its stake in PhaseBio Pharmaceuticals by 41.1% in the 4th quarter. Barclays PLC now owns 21,969 shares of the company’s stock valued at $134,000 after purchasing an additional 6,403 shares during the last quarter. Quantitative Systematic Strategies LLC acquired a new position in PhaseBio Pharmaceuticals in the 4th quarter valued at $67,000. Goldman Sachs Group Inc. raised its stake in PhaseBio Pharmaceuticals by 6.0% in the 4th quarter. Goldman Sachs Group Inc. now owns 116,413 shares of the company’s stock valued at $711,000 after purchasing an additional 6,614 shares during the last quarter. Finally, Acadian Asset Management LLC raised its stake in PhaseBio Pharmaceuticals by 179.4% in the 4th quarter. Acadian Asset Management LLC now owns 13,799 shares of the company’s stock valued at $84,000 after purchasing an additional 8,860 shares during the last quarter. 64.35% of the stock is owned by hedge funds and other institutional investors.

PhaseBio Pharmaceuticals stock traded down $0.38 during mid-day trading on Monday, hitting $4.92. The company had a trading volume of 366,852 shares, compared to its average volume of 602,527. The company has a current ratio of 9.68, a quick ratio of 9.68 and a debt-to-equity ratio of 0.23. PhaseBio Pharmaceuticals has a 12-month low of $2.60 and a 12-month high of $14.08. The company’s fifty day moving average is $4.55 and its 200-day moving average is $4.46. The company has a market capitalization of $145.92 million, a price-to-earnings ratio of -3.01 and a beta of 1.97.

PhaseBio Pharmaceuticals (NASDAQ:PHAS) last released its quarterly earnings data on Tuesday, May 12th. The company reported ($0.52) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.42) by ($0.10). The company had revenue of $0.32 million during the quarter, compared to analysts’ expectations of $0.38 million. PhaseBio Pharmaceuticals had a negative return on equity of 70.50% and a negative net margin of 2,310.60%. As a group, sell-side analysts expect that PhaseBio Pharmaceuticals will post -2.04 EPS for the current fiscal year.

About PhaseBio Pharmaceuticals

PhaseBio Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapies to treat orphan diseases with an initial focus on cardiopulmonary indications. Its lead product candidate is PB2452, which is a reversal agent for the antiplatelet drug ticagrelor that has completed a Phase I clinical trial, as well as developing for the treatment of patients on ticagrelor who are experiencing a major bleeding event or those who require urgent surgery.

Further Reading: What are the advantages of the Stochastic Momentum Index?

Analyst Recommendations for PhaseBio Pharmaceuticals (NASDAQ:PHAS)

Receive News & Ratings for PhaseBio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PhaseBio Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply